Dr. Robert Figlin on The Increasingly Complicated Treatment Paradigm for Renal Cell Carcinoma

Robert A. Figlin, MD, speculates on clinical advances in renal cell carcinomaПодробнее

Dr. Robert Figlin on the Future of Treatment for Patients with RCCПодробнее

Dr. Figlin on Advice for Oncologists Treating RCCПодробнее

The Role of the Tumor Board In Cancer Treatment - Robert Figlin, MD, FACP | Cedars-SinaiПодробнее

Robert Figlin, MD, discusses recent progress in the treatment of renal cell cancer (RCC)Подробнее

Robert Figlin, MD, on treatment of returning metastatic renal cancer when priorly treated with I-OПодробнее

Dr. Figlin on the Evolving Treatment Landscape of Renal Cell CarcinomaПодробнее

Dr. Figlin on TKI Therapy Options in Renal Cell CarcinomaПодробнее

Dr. Figlin Discusses Future of RCC TreatmentПодробнее

Robert Figlin, MD, on appropriate patient types to receive a TKI in the treatment of 1st line RCCПодробнее

Robert Figlin, MD discusses how lenvatanib will fit into the advanced RCC treatment algorithmПодробнее

Dr. Figlin on Sunitinib for Patients With RCCПодробнее

Dr. Figlin on Advances in Immunotherapy for Kidney CancerПодробнее

Robert Figlin, MD, shares exciting potential of current late-stage clinical studies in RCC patientsПодробнее

Dr. Figlin on Next Steps for Research in mRCCПодробнее

Copy of Dr. Figlin Discusses the Future of Kidney Cancer TreatmentПодробнее

Dr. Robert A. Figlin Interview - Renal Cell CarcinomaПодробнее

Robert Figlin, MD, on choosing the most appropriate treatment algorithm for metastatic RCC patientsПодробнее

Treating Renal Cell CarcinomaПодробнее